Polycystic Kidney, Autosomal DominantNCT00410007
The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease
A study testing High Sodium Diet, Low Sodium Diet and Hypertonic saline infusion in people with Polycystic Kidney, Autosomal Dominant, run by Carolina Cannillo at 1 site in Denmark.
Trial summary
The aim of the study is to test the following hypotheses: 1. that the function and/or regulation of AQP2 and /or ENaC in the principal cells is abnormal in autosomal dominant polycystic kidney disease. 2. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Polycystic Kidney, Autosomal Dominant
- What is being tested?
- High Sodium Diet, Low Sodium Diet and Hypertonic saline infusion
- Type of treatment
- Injection or infusion, Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 29 participants
- Where
- 1 siteDenmark
- Study dates
- Oct 2006to Nov 2011
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Caucasian men and women
- age 18-65 years
- BMI between 18,5-30,0 kg/m2
- ADPKD, diagnosed by the following findings on ultra scan:
- for patients without ADPKD family history: > 5 bilateral cysts
- for patients with ADPKD family history: < 30 years: 2 cysts (unilateral or bilateral) 30-60 years: 2 or more bilateral cysts > 60 years: 4 or more bilateral cysts
- Kidney function: stadium 1-4.
Who cannot join
- Other kidney disease
- Anamnestic or clinical signs of acute myocardial infarction, atrial fibrillation, heart valve disease or chronic heart failure
- Anamnestic or clinical signs of disease in lungs, liver,endocrine organs or brain or neoplastic disease
- Family history of rupture of intracerebral aneurisms
- Alcohol or drug abuse
- Smoking
- Medical treatment arat form antihypertensives and oral anticonceptives
- Pregnancy or breastfeeding
Trial locations and contacts
1 site in 1 country.
Denmark1 site
Department of Medical Research, Holstebro Hospital
Holstebro, 7500
About this study
Official title: The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease, During Basal Conditions and After Hypertonic Saline Infusion.
The aim of the study is to test the following hypotheses:
- that the function and/or regulation of AQP2 and /or ENaC in the principal cells is abnormal in autosomal dominant polycystic kidney disease.
- if an abnormal function of the principal cells is present in autosomal dominant polycystic kidney disease, this will become more pronounced at high and low sodium intake.
Read the detailed description
Recruitment:
The patients with ADPKD are recruited from the Outpatient Nephrology Clinic of the Department of Medicine, Holstebro Hospital (Holstebro, Denmark). The control subjects are recruited by advertising in public institutions and private companies.
Number of Subjects:
A difference in u-AQP2CR of 40 ng/mmol is considered the minimal relevant difference. A sample size of 10 subjects, who can be evaluated, has 80% power to detect this difference assuming a level of significance of 5% and an SD of 30 ng/mmol. Because a few subjects are expected to drop out, 14-15 subjects will be included in each group.
Experimental Procedure Before the Study Day:
Five days before the study day, the subjects collect a standardized, HS (300 mmol sodium/day/17.5 g salt/day) or LS (30 mmol sodium/day/1.8 g salt/day), 4-day diet from the hospital kitchen. Depending on the individually estimated energy requirement, the participants are given either a diet of 8,000 or 11,000 kJ/day. The energy distribution is 55% carbohydrates, 15% proteins, and 30% lipids. The 4-day diet is started the following morning. The fluid intake is also standardized during the 4 days. The subjects are asked to drink exactly 250 ml/1,000 kJ/day and to abstain from coffee, tea, and alcoholic beverages. The subjects are instructed to keep their physical activity unchanged during the two experiments and to abstain from hard training. The subjects have to collect their urine for 24 h the day before the study day.
Experimental Procedure on the Study Day:
On the study day, the subjects are asked to drink 175 ml of water every 30 min from 7:00 AM. The subjects arrive at the department at 8:00 AM. Peripheral iv lines are inserted into the antecubital veins of both forearms, one for infusion of 51Cr-EDTA and hypertonic saline, and one for withdrawal of blood samples. The subjects will be kept in the supine position from 8:00 AM to 1:30 PM except during voiding, which will take place in the sitting or standing position. At 8:30 AM, a priming dose of 51Cr-EDTA is administered, followed by sustained infusion. After 60 min of equilibration, the study will continue with five clearance periods, the first two of 30-min duration (P1-P2), the last three of 60-min duration (P3-P5). The first two clearance periods are baseline periods. At 10:30 AM, 7 ml/kg of 3% saline is given over 30 min. Blood pressure and heart rate are measured every 30 min from 9:30 AM to 1:30 PM. Urine is collected in each clearance period and analyzed for sodium, osmolality, u-AQP2, u-ENaC-betaCR, u-cAMP, u-PGE2, and 51CrEDTA. Blood samples will be drawn every 30 min from 9:30 AM to 10:30 AM and every hour from 11:30 AM to 1:30 PM, and will be analyzed for sodium, osmolality, and 51Cr-EDTA. In addition, analysis of p-AVP, p-Renin, p-ANG II, p-Aldo, p-ANP, and p-BNP will be performed from blood samples drawn at 10:30 AM, 11:30 AM, 12:30 PM, and 1:30 PM.
Statistics:
Statistical analyses will be performed using SPSS version 15 (SPSS, Chicago, IL). Single baseline values are obtained by taking the weighted average of the measurements from the two baseline periods. The baseline values of the two groups will be compared by Student's t-test. The baseline values during HS and LS intake will be compared by paired samples t-tests. The investigators will use the "General Linear Model Repeated Measures" procedure in SPSS with time as the within-subject factor and group as the between-subject factor to compare the effect variables in patients and controls. The changes in response to the hypertonic saline infusion in each group will be analyzed with the General Linear Model Repeated Measures procedure with time as the within-subject factor and paired samples t-tests with Bonferroni correction as post hoc tests. P values Recruitment The patients with ADPKD will be recruited from the Outpatient Nephrology Clinic of the Department of Medicine, Holstebro Hospital (Holstebro, Denmark). The control subjects will be recruited by advertising in public institutions and private companies.
Number of Subjects A difference in u-AQP2CR of 40 ng/mmol is considered the minimal relevant difference. A sample size of 10 subjects, who could be evaluated, has 80% power to detect this difference assuming a level of significance of 5% and an SD of 30 ng/mmol. Because a few subjects are expected to drop out, 14-15 subjects will be included in each group.
Experimental Procedure Before the Study Day Five days before the study day, the subjects will collect a standardized, HS (300 mmol sodium/day/17.5 g salt/day) or LS (30 mmol sodium/day/1.8 g salt/day), 4-day diet from the hospital kitchen. Depending on the individually estimated energy requirement, the participants will be given either a diet of 8,000 or 11,000 kJ/day. The energy distribution will be 55% carbohydrates, 15% proteins, and 30% lipids. The 4-day diet will start the following morning. The fluid intake is also standardized during the 4 days. The subjects are asked to drink exactly 250 ml/1,000 kJ/day and to abstain from coffee, tea, and alcoholic beverages. The subjects will be instructed to keep their physical activity unchanged during the two experiments and to abstain from hard training. The subjects have to collect their urine for 24 h the day before the study day.
Experimental Procedure on the Study Day On the study day, the subjects are asked to drink 175 ml of water every 30 min from 7:00 AM. The subjects arrive at the department at 8:00 AM. Peripheral iv lines will be inserted into the antecubital veins of both forearms, one for infusion of 51Cr-EDTA and hypertonic saline, and one for withdrawal of blood samples. The subjects will be kept in the supine position from 8:00 AM to 1:30 PM except during voiding, which will take place in the sitting or standing position. At 8:30 AM, a priming dose of 51Cr-EDTA is administered, followed by sustained infusion. After 60 min of equilibration, the study will continue with five clearance periods, the first two of 30-min duration (P1-P2), the last three of 60-min duration (P3-P5). The first two clearance periods are baseline periods. At 10:30 AM, 7 ml/kg of 3% saline is given over 30 min. Blood pressure and heart rate will be measured every 30 min from 9:30 AM to 1:30 PM. Urine is collected in each clearance period and analyzed for sodium, osmolality, u-AQP2, u-ENaC-betaCR, u-cAMP, u-PGE2, and 51CrEDTA. Blood samples will be drawn every 30 min from 9:30 AM to 10:30 AM and every hour from 11:30 AM to 1:30 PM, and will be analyzed for sodium, osmolality, and 51Cr-EDTA. In addition, analysis of p-AVP, p-Renin, p-ANG II, p-Aldo, p-ANP, and p-BNP will be performed from blood samples drawn at 10:30 AM, 11:30 AM, 12:30 PM, and 1:30 PM.
Statistics Statistical analyses will be performed using SPSS version 15 (SPSS, Chicago, IL). Single baseline values are obtained by taking the weighted average of the measurements from the two baseline periods. The baseline values of the two groups will be compared by Student's t-test. The baseline values during HS and LS intake will be compared by paired samples t-tests. The investigators will use the "General Linear Model Repeated Measures" procedure in SPSS with time as the within-subject factor and group as the between-subject factor to compare the effect variables in patients and controls. The changes in response to the hypertonic saline infusion in each group will be analyzed with the General Linear Model Repeated Measures procedure with time as the within-subject factor and paired samples t-tests with Bonferroni correction as post hoc tests. P values ≤0.05 will be considered significant.
- Conditions
- Polycystic Kidney, Autosomal Dominant
- Being tested
- High Sodium Diet, Low Sodium Diet, Hypertonic saline infusion
- Keywords
- ADPKD, Urinary Aquaporin-2, ENaC, Fractional sodium excretion, High/low sodium diet
- Medical subject headings
- Polycystic Kidney, Autosomal Dominant
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
High Sodium DietBehavioural
250-350 mmol
Low Sodium DietBehavioural
25-35 mmol
Hypertonic saline infusionBehavioural
7 ml/ kg of 3% saline were given over 30 minutes.
| Study group | Role | What they receive |
|---|---|---|
| Patients with ADPKD, HS | Other | Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given. Receives: Behavioral: High Sodium Diet; Behavioral: Hypertonic saline infusion |
| Patients with ADPKD, LS | Other | Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given. Receives: Behavioral: Low Sodium Diet; Behavioral: Hypertonic saline infusion |
| Healthy Control Subjects, HS | Other | Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given. Receives: Behavioral: High Sodium Diet; Behavioral: Hypertonic saline infusion |
| Healthy Control Subjects, LS | Other | Each subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given. Receives: Behavioral: Low Sodium Diet; Behavioral: Hypertonic saline infusion |
What is being measured
The primary outcome is the main question the study is designed to answer.
u-AQP-2CR
Urinary Aquaporin-2 corrected for creatinine
Measured: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
Secondary outcomes (8)
u-ENaC (beta)CR
Urinary ENaC (beta) corrected for creatinine
Measured: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
FENa
fractional sodium excretion
Measured: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
CH2O
Free water excretion
Measured: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
u-cAMP
urinary excretion of cAMP
Measured: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
uPGE-2
urinary excretion of PGE-2
Measured: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
GFR
glomerular filtration rate
Measured: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
p-vasopressin
plasma concentration of vasopressin
Measured: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
p-aldosterone.
plasma concentration of aldosterone
Measured: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted12 Dec 2006 (estimated)
- Study startOct 2006
- Primary completionOct 2010
- Study completionNov 2011
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Polycystic Kidney, Autosomal DominantStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 29 participants (actual)
Sponsor and investigators
- Lead sponsor
- Carolina Cannillo
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Carolina Cannillo, Regional Hospital Holstebro
- Investigators
- Erling B. Pedersen, Professor, Study chair, Department of Medical Research, Holstebro Hospital, DenmarkCarolina C. Graffe, MD, Principal investigator, Department of Medical Research, Holstebro Hospital, Denmark
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00410007
- Sponsor's protocol ID
- med.res.hos.2006.cc.03
- Status last verified
- Mar 2018
- First submitted
- 10 Dec 2006
- Last updated
- 20 Mar 2018
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Mar 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of High and Low Sodium Intake on Urinary Aquaporin-2 in Autosomal Dominant Polycystic Kidney Disease, During Basal Conditions and After Hypertonic Saline Infusion.
- ClinicalTrials.gov ID
- NCT00410007
- Acronym / sponsor ID
- med.res.hos.2006.cc.03
- Conditions
- Polycystic Kidney, Autosomal Dominant
- Keywords
- ADPKD, Urinary Aquaporin-2, ENaC, Fractional sodium excretion, High/low sodium diet
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 29 participants (actual)
- Lead sponsor
- Carolina CannilloUniversity, hospital or other
- Study start
- Oct 2006
- Primary completion
- Oct 2010 (actual)
- Study completion
- Nov 2011 (actual)
- First posted
- 12 Dec 2006 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The aim of the study is to test the following hypotheses:
- that the function and/or regulation of AQP2 and /or ENaC in the principal cells is abnormal in autosomal dominant polycystic kidney disease.
- if an abnormal function of the principal cells is present in autosomal dominant polycystic kidney disease, this will become more pronounced at high and low sodium intake.
Detailed description
Recruitment:
The patients with ADPKD are recruited from the Outpatient Nephrology Clinic of the Department of Medicine, Holstebro Hospital (Holstebro, Denmark). The control subjects are recruited by advertising in public institutions and private companies.
Number of Subjects:
A difference in u-AQP2CR of 40 ng/mmol is considered the minimal relevant difference. A sample size of 10 subjects, who can be evaluated, has 80% power to detect this difference assuming a level of significance of 5% and an SD of 30 ng/mmol. Because a few subjects are expected to drop out, 14-15 subjects will be included in each group.
Experimental Procedure Before the Study Day:
Five days before the study day, the subjects collect a standardized, HS (300 mmol sodium/day/17.5 g salt/day) or LS (30 mmol sodium/day/1.8 g salt/day), 4-day diet from the hospital kitchen. Depending on the individually estimated energy requirement, the participants are given either a diet of 8,000 or 11,000 kJ/day. The energy distribution is 55% carbohydrates, 15% proteins, and 30% lipids. The 4-day diet is started the following morning. The fluid intake is also standardized during the 4 days. The subjects are asked to drink exactly 250 ml/1,000 kJ/day and to abstain from coffee, tea, and alcoholic beverages. The subjects are instructed to keep their physical activity unchanged during the two experiments and to abstain from hard training. The subjects have to collect their urine for 24 h the day before the study day.
Experimental Procedure on the Study Day:
On the study day, the subjects are asked to drink 175 ml of water every 30 min from 7:00 AM. The subjects arrive at the department at 8:00 AM. Peripheral iv lines are inserted into the antecubital veins of both forearms, one for infusion of 51Cr-EDTA and hypertonic saline, and one for withdrawal of blood samples. The subjects will be kept in the supine position from 8:00 AM to 1:30 PM except during voiding, which will take place in the sitting or standing position. At 8:30 AM, a priming dose of 51Cr-EDTA is administered, followed by sustained infusion. After 60 min of equilibration, the study will continue with five clearance periods, the first two of 30-min duration (P1-P2), the last three of 60-min duration (P3-P5). The first two clearance periods are baseline periods. At 10:30 AM, 7 ml/kg of 3% saline is given over 30 min. Blood pressure and heart rate are measured every 30 min from 9:30 AM to 1:30 PM. Urine is collected in each clearance period and analyzed for sodium, osmolality, u-AQP2, u-ENaC-betaCR, u-cAMP, u-PGE2, and 51CrEDTA. Blood samples will be drawn every 30 min from 9:30 AM to 10:30 AM and every hour from 11:30 AM to 1:30 PM, and will be analyzed for sodium, osmolality, and 51Cr-EDTA. In addition, analysis of p-AVP, p-Renin, p-ANG II, p-Aldo, p-ANP, and p-BNP will be performed from blood samples drawn at 10:30 AM, 11:30 AM, 12:30 PM, and 1:30 PM.
Statistics:
Statistical analyses will be performed using SPSS version 15 (SPSS, Chicago, IL). Single baseline values are obtained by taking the weighted average of the measurements from the two baseline periods. The baseline values of the two groups will be compared by Student's t-test. The baseline values during HS and LS intake will be compared by paired samples t-tests. The investigators will use the "General Linear Model Repeated Measures" procedure in SPSS with time as the within-subject factor and group as the between-subject factor to compare the effect variables in patients and controls. The changes in response to the hypertonic saline infusion in each group will be analyzed with the General Linear Model Repeated Measures procedure with time as the within-subject factor and paired samples t-tests with Bonferroni correction as post hoc tests. P values Recruitment The patients with ADPKD will be recruited from the Outpatient Nephrology Clinic of the Department of Medicine, Holstebro Hospital (Holstebro, Denmark). The control subjects will be recruited by advertising in public institutions and private companies.
Number of Subjects A difference in u-AQP2CR of 40 ng/mmol is considered the minimal relevant difference. A sample size of 10 subjects, who could be evaluated, has 80% power to detect this difference assuming a level of significance of 5% and an SD of 30 ng/mmol. Because a few subjects are expected to drop out, 14-15 subjects will be included in each group.
Experimental Procedure Before the Study Day Five days before the study day, the subjects will collect a standardized, HS (300 mmol sodium/day/17.5 g salt/day) or LS (30 mmol sodium/day/1.8 g salt/day), 4-day diet from the hospital kitchen. Depending on the individually estimated energy requirement, the participants will be given either a diet of 8,000 or 11,000 kJ/day. The energy distribution will be 55% carbohydrates, 15% proteins, and 30% lipids. The 4-day diet will start the following morning. The fluid intake is also standardized during the 4 days. The subjects are asked to drink exactly 250 ml/1,000 kJ/day and to abstain from coffee, tea, and alcoholic beverages. The subjects will be instructed to keep their physical activity unchanged during the two experiments and to abstain from hard training. The subjects have to collect their urine for 24 h the day before the study day.
Experimental Procedure on the Study Day On the study day, the subjects are asked to drink 175 ml of water every 30 min from 7:00 AM. The subjects arrive at the department at 8:00 AM. Peripheral iv lines will be inserted into the antecubital veins of both forearms, one for infusion of 51Cr-EDTA and hypertonic saline, and one for withdrawal of blood samples. The subjects will be kept in the supine position from 8:00 AM to 1:30 PM except during voiding, which will take place in the sitting or standing position. At 8:30 AM, a priming dose of 51Cr-EDTA is administered, followed by sustained infusion. After 60 min of equilibration, the study will continue with five clearance periods, the first two of 30-min duration (P1-P2), the last three of 60-min duration (P3-P5). The first two clearance periods are baseline periods. At 10:30 AM, 7 ml/kg of 3% saline is given over 30 min. Blood pressure and heart rate will be measured every 30 min from 9:30 AM to 1:30 PM. Urine is collected in each clearance period and analyzed for sodium, osmolality, u-AQP2, u-ENaC-betaCR, u-cAMP, u-PGE2, and 51CrEDTA. Blood samples will be drawn every 30 min from 9:30 AM to 10:30 AM and every hour from 11:30 AM to 1:30 PM, and will be analyzed for sodium, osmolality, and 51Cr-EDTA. In addition, analysis of p-AVP, p-Renin, p-ANG II, p-Aldo, p-ANP, and p-BNP will be performed from blood samples drawn at 10:30 AM, 11:30 AM, 12:30 PM, and 1:30 PM.
Statistics Statistical analyses will be performed using SPSS version 15 (SPSS, Chicago, IL). Single baseline values are obtained by taking the weighted average of the measurements from the two baseline periods. The baseline values of the two groups will be compared by Student's t-test. The baseline values during HS and LS intake will be compared by paired samples t-tests. The investigators will use the "General Linear Model Repeated Measures" procedure in SPSS with time as the within-subject factor and group as the between-subject factor to compare the effect variables in patients and controls. The changes in response to the hypertonic saline infusion in each group will be analyzed with the General Linear Model Repeated Measures procedure with time as the within-subject factor and paired samples t-tests with Bonferroni correction as post hoc tests. P values ≤0.05 will be considered significant.
Study design
- Primary purpose
- Other
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Double blind (participant, investigator)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Patients with ADPKD, HS | Other | Behavioral: High Sodium Diet, Behavioral: Hypertonic saline infusionEach subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given. |
| Patients with ADPKD, LS | Other | Behavioral: Low Sodium Diet, Behavioral: Hypertonic saline infusionEach subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given. |
| Healthy Control Subjects, HS | Other | Behavioral: High Sodium Diet, Behavioral: Hypertonic saline infusionEach subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given. |
| Healthy Control Subjects, LS | Other | Behavioral: Low Sodium Diet, Behavioral: Hypertonic saline infusionEach subject was studied on 2 separate days at least 3 weeks apart. During 4 days before the study day, the subjects consumed either a high sodium diet or a low sodium diet in randomized order (HS-LS/ LS-HS). On the study day a hypertonic saline infusion was given. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Caucasian men and women
- age 18-65 years
- BMI between 18,5-30,0 kg/m2
- ADPKD, diagnosed by the following findings on ultra scan:
- Kidney function: stadium 1-4.
Key exclusion criteria (8 listed)
- Other kidney disease
- Anamnestic or clinical signs of acute myocardial infarction, atrial fibrillation, heart valve disease or chronic heart failure
- Anamnestic or clinical signs of disease in lungs, liver,endocrine organs or brain or neoplastic disease
- Family history of rupture of intracerebral aneurisms
- Alcohol or drug abuse
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| High Sodium Diet250-350 mmol | Behavioural | Healthy Control Subjects, HS, Patients with ADPKD, HS |
| Low Sodium Diet25-35 mmol | Behavioural | Healthy Control Subjects, LS, Patients with ADPKD, LS |
| Hypertonic saline infusion7 ml/ kg of 3% saline were given over 30 minutes. | Behavioural | Healthy Control Subjects, HS, Healthy Control Subjects, LS, Patients with ADPKD, HS, Patients with ADPKD, LS |
Primary outcome
u-AQP-2CR
Time frame: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
Urinary Aquaporin-2 corrected for creatinine
8 secondary outcomes
u-ENaC (beta)CR
Time frame: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
FENa
Time frame: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
CH2O
Time frame: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
u-cAMP
Time frame: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
uPGE-2
Time frame: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
GFR
Time frame: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
p-vasopressin
Time frame: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
p-aldosterone.
Time frame: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Mar 2018.
Related trials for Polycystic Kidney, Autosomal Dominant
RecruitingObservational study
Hypertension in Children and Young People at Risk of Autosomal Dominant Polycystic Kidney Disease
Autosomal Dominant Polycystic Kidney Disease (ADPKD
Active, not recruitingObservational study
Role of ROS and cAMP-PKA Biomarkers in ADPKD
Autosomal Dominant Polycystic Kidney Disease
Not yet recruitingPhase 1
A Study to Investigate the Pharmacokinetics of JMKX003142 in Healthy Participants and Participants With Hepatic Impairment
ADPKD (Autosomal Dominant Polycystic Kidney Disease), Renal Edema
RecruitingPhase 1
Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RecruitingObservational study
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Rare Disorders, Undiagnosed Disorders
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Erling B. Pedersen, Professor study chair
Department of Medical Research, Holstebro Hospital, Denmark
Carolina C. Graffe, MD principal investigator
Department of Medical Research, Holstebro Hospital, Denmark
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing High Sodium Diet, Low Sodium Diet and Hypertonic saline infusion in people with Polycystic Kidney, Autosomal Dominant, run by Carolina Cannillo at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 20 Mar 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
u-AQP-2CR (time frame: Before and after hypertonic saline infusion after 4 days on high and low sodium diet, respectively.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Mar 2018.